ARCHIVES

NEJM Papers, Interview With NCI’s Doroshow, Provide Justification For Regulatory Action on ESAs.

This article is from The Cancer Letter archive.

Vol. 33 No. 23 | June 15, 2007

Download PDF Visit The Full Archive

Related Articles

Critics of FDA misunderstand Bayesian analysis, statisticians say.

August 5, 2005

In Senate testimony, NCI director uses survival rate as measure of progress for goal to “eliminate suffering and death due to cancer.”

July 29, 2005

Texts Of Workshop Report Summarized

November 8, 1996

New Compounds To Treat Gleevec-Resistant CML

January 26, 2007

In Brief: NCI Gets $867 Million From Conferees; Grants To Be Funded At 41-42% Including Some Holdovers

July 29, 1977

Burzynski, Monaco Clashed In Court

June 5, 1992